Abivax Analyst Price Targets - Benzinga

Abivax SA

ABVXNASDAQ

Trade with Public

Trade with Public

$118.64

2.692.32%

At close: Sep 11, 5:00 PM EST

$118.00

-0.64-0.54%

After Hours: Sep 11, 4:12 PM EST

Earnings: H1 2026 Earnings in 7 days from now on Mon Sep 21st, after the market close

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Compare Options Stock Report

Abivax Analyst Price Targets

Wall Street analyst price targets and consensus rating for Abivax (ABVX).

Price Target Range — 11 Quarters

Analyst Consensus — 16 Analysts

3S.Buy

12Buy

1Hold

Consensus RatingMarket Outperform# Analysts16Avg. Consensus PT$120Upside to Avg. PT+1.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 10, 2026	Goldman Sachs	Rajan Sharma	Initiate	Buy	$155
Jul 9, 2026	Piper Sandler	Allison Bratzel	PT Raise	Overweight	$165→$175
Jul 2, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$135→$155
Jul 1, 2026	Citizens	Jason N. Butler	Maintained	Market Outperform	$187
Jun 30, 2026	Jefferies	Faisal Khurshid	Upgrade	Hold→Buy	$108→$158
Jun 30, 2026	Leerink Partners	Thomas Smith	PT Raise	Outperform	$140→$148
Jun 30, 2026	Wedbush	David Nierengarten	PT Raise	Neutral	$90→$110
Jun 30, 2026	BTIG	Julian Harrison	PT Raise	Buy	$150→$175
Jun 16, 2026	BTIG	Julian Harrison	Maintained	Buy	$150
Jun 2, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$140→$135
Jun 2, 2026	Jefferies	Faisal Khurshid	Downgrade	Buy→Hold	$160→$90
Jun 2, 2026	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$145→$132
Jun 2, 2026	Wedbush	David Nierengarten	Upgrade	Underperform→Neutral	$110→$90
Jun 2, 2026	Citizens	Jason N. Butler	PT Raise	Market Outperform	$131→$187
Jun 2, 2026	BTIG	Julian Harrison	Maintained	Buy	$150
May 26, 2026	Citizens	Jason N. Butler	Maintained	Market Outperform	$131
Mar 24, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$142→$148
Mar 16, 2026	Jefferies	Faisal Khurshid	Initiate	Buy	$160
Feb 25, 2026	BTIG	Julian Harrison	Maintained	Buy	$150
Feb 24, 2026	Wedbush	David Nierengarten	Initiate	Underperform	$110

More with Benzinga EdgeGet Access

Analyst Ratings News

This Amer Sports Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiate: Buy—Abivax ($155), Amer Sports ($42) and more

Avi Kapoor

PRO
Goldman Sachs Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $155

Goldman Sachs analyst Rajan Sharma initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and announces Price Target of $155.

Benzinga Newsdesk

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.

Vandana Singh

PRO
Piper Sandler Maintains Overweight on Abivax, Raises Price Target to $175

Piper Sandler analyst Allison Bratzel maintains Abivax (NASDAQ:ABVX) with a Overweight and raises the price target from $165 to $175.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Abivax, Raises Price Target to $155

Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $135 to $155.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Abivax, Maintains $187 Price Target

Citizens analyst Jason N. Butler reiterates Abivax (NASDAQ:ABVX) with a Market Outperform and maintains $187 price target.

Benzinga Newsdesk